The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.

Saved in:
Bibliographic Details
Title: The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Authors: Giudice E; Women's Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, 20892, USA.; Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168, Rome, Italy., Huang TT; Women's Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, 20892, USA., Nair JR; Women's Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, 20892, USA., Zurcher G; Women's Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, 20892, USA., McCoy A; Women's Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, 20892, USA., Nousome D; Center for Cancer Research Collaborative Bioinformatics Resource, CCR, NCI, NIH, Bethesda, MD, 20892, USA., Radke MR; Department of Ob/Gyn, University of Washington, Seattle, WA, 98195, USA., Swisher EM; Department of Ob/Gyn, University of Washington, Seattle, WA, 98195, USA., Lipkowitz S; Women's Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, 20892, USA., Ibanez K; Women's Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, 20892, USA., Donohue D; Statistical Consulting and Scientific Programming Group, Computer and Statistical Services, Data Management Services, Inc. (a BRMI company), NCI, Frederick, MD, 21702, USA., Malys T; Statistical Consulting and Scientific Programming Group, Computer and Statistical Services, Data Management Services, Inc. (a BRMI company), NCI, Frederick, MD, 21702, USA., Lee MJ; Developmental Therapeutics Branch, CCR, NCI, NIH, Bethesda, MD, 20892, USA., Redd B; Clinical Image Processing Service, Department of Radiology and Imaging Sciences, CCR, NCI, NIH, Bethesda, MD, 20892, USA., Levy E; Interventional Radiology, CCR, NCI, NIH, Bethesda, MD, 20892, USA., Rastogi S; Developmental Therapeutics Branch, CCR, NCI, NIH, Bethesda, MD, 20892, USA., Sato N; Developmental Therapeutics Branch, CCR, NCI, NIH, Bethesda, MD, 20892, USA., Trepel JB; Developmental Therapeutics Branch, CCR, NCI, NIH, Bethesda, MD, 20892, USA., Lee JM; Women's Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, 20892, USA. leej6@mail.nih.gov.
Source: Nature communications [Nat Commun] 2024 Mar 30; Vol. 15 (1), pp. 2805. Date of Electronic Publication: 2024 Mar 30.
Publication Type: Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2041-1723
DOI:10.1038/s41467-024-47215-6